Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Randomized Phase 2 Trial Of AG013736 Or Bevacizumab In Combination With Paclitaxel And Carboplatin As First Line Treatment For Patients With Advanced Non Small Cell Lung Cancer

NCT00600821 is registered in ClinicalTrials.gov with Pfizer as lead sponsor.

NCT NCT00600821
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00600821 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Randomized Phase 2 Trial Of AG013736 Or Bevacizumab In Combination With Paclitaxel And Carboplatin As First Line Treatment For Patients With Advanced Non Small Cell Lung Cancer
Lead sponsor
Pfizer
Phase
Phase 2
Overall status
Completed
Start date
April 30, 2008
Completion date
October 31, 2012
Enrollment
118 (actual)
Sites
44

Conditions

As the registry lists them; a condition with its own page is linked.

adenocarcinoma, non-small-cell lung carcinoma